



### New Programs

who have received prior treatment with fluoropyrimidine-based chemotherapy and anti-VEGF monoclonal antibody (i.e., bevacizumab) and/or anti-EGFR monoclonal antibody (i.e., panitumumab, cetuximab). Each 28-day cycle includes oral trifluridine-tipiracil twice daily on days 1-5 and days 8-12, and intravenous bevacizumab on days 1 and 15.

Approval of this new treatment program is based on the phase III randomized, controlled SUNLIGHT trial.<sup>1,2</sup> A significant improvement in overall survival was demonstrated with the use of trifluridine-tipiracil plus bevacizumab compared with trifluridine-tipiracil alone (10.8 months vs. 7.5 months, hazard ratio [HR] = 0.61). Trifluridine-tipiracil monotherapy previously demonstrated an improvement in overall survival compared to best supportive care.<sup>2</sup> Adverse events of any cause that led to discontinuation in the SUNLIGHT trial were reported in 12.6% of patients in both treatment groups. Dose reductions occurred in 16.3% of patients in the trifluridine-tipiracil plus bevacizumab group and in 12.2% receiving trifluridine-tipiracil alone.<sup>1</sup>

### Skin & Melanoma

**Nivolumab-Relatlimab for Unresectable or Metastatic Melanoma (USMAVNIVRE)** – The BC Cancer Skin and Melanoma Tumour Group is introducing nivolumab-relatlimab as a new treatment option for patients with unresectable or metastatic melanoma. Patients are eligible if they had a disease-free interval of six months or greater with prior neoadjuvant or adjuvant immunotherapy. In the advanced setting, patients are eligible to receive one of nivolumab-relatlimab, pembrolizumab, nivolumab, or combination ipilimumab with nivolumab, but not the sequential use of these agents. BC Cancer Compassionate Access Program (CAP) approval is required prior to treatment.

Nivolumab-relatlimab is a fixed-dose combination of two monoclonal antibodies that target distinct inhibitory immune checkpoints: programmed cell death 1 (PD-1) (nivolumab) and lymphocyte-activation gene 3 (LAG-3) (relatlimab).<sup>3</sup> LAG-3 is a receptor protein which negatively regulates T-cell function and provides tumours with an immune escape in the tumour microenvironment. By binding to the LAG-3 T-cell receptor and blocking its interaction with ligands, relatlimab reduces LAG-3 pathway inhibition of the immune response and promotes T-cell proliferation and cytokine secretion. The combination of nivolumab and relatlimab results in increased T-cell activation compared to the activity of either antibody alone. See the Cancer Drug Manual section of this issue for more information on nivolumab-relatlimab.

Approval of this treatment program is supported by evidence from the phase II-III, randomized, controlled RELATIVITY-047 trial.<sup>4,5</sup> At a median follow-up of 19.3 months, treatment with nivolumab-relatlimab demonstrated a statistically significant and clinically important progression-free survival benefit when compared with nivolumab monotherapy (HR=0.78). Adverse events were consistent with immune system overactivation, and no new safety signals were demonstrated. While the rate of grade 3 or 4 treatment-related adverse events was higher with nivolumab-relatlimab compared with nivolumab (21.1% vs. 11.1%), it was lower than that reported with combination treatment with a CTLA-4 inhibitor and PD-1 inhibitor.<sup>6</sup>

#### References

- 1 Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. *N Engl J Med* 2023;388(18):1657-1667. <https://doi.org/10.1056/NEJMoa2214963>
- 2 CADTH Reimbursement Recommendation. Trifluridine-tipiracil (Lonsurf®). *Canadian Journal of Health Technologies* 2024;4(3). <https://doi.org/10.51731/cjht.2024.858>
- 3 Nivolumab-relatlimab monograph. 01 November 2024. In: BC Cancer Drug Manual®. Badry, Nadine (editor). BC Cancer. Vancouver, British Columbia. Available at <http://www.bccancer.bc.ca/>

## Editor's Choice

### New Programs

- 4 Long GV, Hodi FS, Lipson EJ, et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. *NEJM Evid* 2023;2(4). <https://doi.org/10.1056/EVIDoa2200239>
- 5 CADTH Reimbursement Recommendation. Nivolumab and relatlimab (Opdualag®). *Canadian Journal of Health Technologies* 2024;4(2). <https://doi.org/10.51731/cjht.2024.836>
- 6 Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. *N Engl J Med* 2022;386:24-34. <https://doi.org/10.1056/NEJMoa2109970>

## Practice Standards and Policies

### Updated: Influenza Vaccine Recommendations

The **BC Cancer Influenza Vaccine Recommendations for Adults with Cancer** have been updated for the 2024-2025 influenza season. They are available on the BC Cancer website in the [Supportive Care](#) section of the Cancer Management Manual and on the [Immunotherapy](#) and [Supportive Care](#) pages in the Chemotherapy Protocols section.

As in the previous flu season, patients should be offered an age-appropriate inactivated influenza vaccine. The quadrivalent inactivated influenza vaccine continues to be recommended vaccine for adults under 65 years of age. This year, the recommended vaccine for all adults 65 years of age and older, irrespective of whether they are residing in the community or in residential care, is the adjuvanted trivalent inactivated influenza vaccine. The high-dose quadrivalent inactivated influenza vaccine is no longer covered by the province for any patient population.

### Updated: Policy III-60: Infusion-Related Drug Reaction Management

**Nivolumab-relatlimab** has been added to the Appendix to Systemic Therapy **Policy III-60: Infusion-Related Drug Reaction Management – Physician or Nurse Practitioner Coverage During Delivery of Selected Systemic Therapy Drugs**.

All Systemic Therapy policies are on the Shared Health Organizations Portal ([SHOP](#)) BC Cancer page.

## Professional Practice Nursing

### Updated: Immunotherapy Nursing Process

Provincial Professional Practice Nursing has updated the **Immunotherapy Nursing Process** document located on the [Immunotherapy](#) page in the Nursing section of the BC Cancer website.

Updates include:

- Links to the SCIMMUNE patient handout, immunotherapy alert card and patient letter
- Key assessment considerations related to immune-mediated adverse events
- NCI CTCAE replaces NCI to reflect terminology used in the NCI CTCAE grading procedure

Please contact [BCCancerPPNAdmin@phsa.ca](mailto:BCCancerPPNAdmin@phsa.ca) for queries or concerns.

All documents are available in the [Cancer Drug Manual<sup>®</sup>](#) on the BC Cancer website.

### New Documents

The **Nivolumab-Relatlimab Monograph** and **Patient Handout** have been developed. Expert review was provided by Dr. Alison Wepler (medical oncologist, BC Cancer Skin & Melanoma Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). Nivolumab-relatlimab is a fixed-dose combination of two checkpoint inhibitors used as immunotherapy in the treatment of melanoma. The usual dosing is 480 mg-160 mg IV once every 4 weeks and follows BC Cancer protocol USMAVNIVRE.

Highlights from these documents include:

- severe ***immune-mediated adverse reactions*** are reported; onset usually occurs during the treatment period, but symptoms may be delayed
- anemia is commonly reported
- rare but potentially fatal side effects include multi-organ failure, pneumonitis, and hemophagocytic lymphohistiocytosis

**Nivolumab-relatlimab** has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Relugolix Interim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Krista Noonan (medical oncologist, BC Cancer Genitourinary Tumour Group) and Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). Relugolix is an oral GnRH receptor antagonist. It is used in the treatment of advanced prostate cancer. Treatment starts with a loading dose of 360 mg on day 1, followed by the usual dose of 120 mg PO once daily thereafter.

Highlights from these documents include:

- it is not necessary to add an anti-androgen to mitigate clinical flare when initiating relugolix
- treatment interruptions longer than 7 days require a repeat loading dose once treatment is resumed
- dose modification may be required for some drug-drug interactions
- risk of QTc prolongation is increased in patients with congenital long QT syndrome, history of QT prolongation, or those taking medications known to prolong QTc interval

**Relugolix** has been added to the **Auxiliary Label List** and evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

## Revised Documents

### Tarlatamab Interim Monograph

*Supply and Storage:* added marketed supply and deleted SAP supply

### Trastuzumab Emtansine Monograph

*Side Effects:* added paragraph regarding extravasation after the Side Effects table

### Trifluridine-Tipiracil Monograph

*Dosage Guidelines:* updated references to include BC Cancer protocols GIAVTTB and GIGAVTT

### Chemotherapy Preparation and Stability Chart

*Bendamustine:* added new brand (Eugia)

*Calaspargase pegol:* new addition (pegylated asparaginase *E. coli*)

*Crisantaspase recombinant:* updated nomenclature to include “recombinant” in the drug name

*Tarlatamab:* added marketed supply and deleted SAP supply

*Thiotepa:* added marketed supply and deleted SAP supply

**Extravasation Hazard Table:** revised trastuzumab emtansine (changed back to irritant pending review of new evidence)

### Hazardous Drug List BC Cancer Addendum

*Tarlatamab:* now marketed; will be moving from SAP list to main Provincial HA HD List

## Drug Shortages

The following are updates of drug supply shortages in BC. Full details about new, updated or resolved drug shortages, including recommended treatment alternatives, are found in the *Briefing Notes* and email communications previously circulated to BC Cancer and the Community Oncology Network (CON).

## New

### Doxorubicin Pegylated Liposomal

*Adapted from BC Cancer Briefing Note: 17 October 2024*

There is a potential shortage of doxorubicin pegylated liposomal vials due to manufacturing disruptions. The manufacturer, Taro, anticipates that the shortage duration may last until the end of December 2024. In the meantime, Taro has obtained Health Canada approval to import supply from the US. Another manufacturer, Baxter, may also have limited supplies available. As a result, there may be short-term and intermittent supply issues.

At BC Cancer doxorubicin pegylated liposomal is used in the treatment of Hodgkin lymphoma, Kaposi sarcoma, and gynecologic cancers (epithelial ovarian, primary peritoneal and fallopian tube). If supply issues arise, consider prioritizing supply for: 1/ new patients with Hodgkin lymphoma (as there are no other clear alternatives); and 2/ patients receiving ongoing treatment for all indications. Potential treatment alternatives should be discussed with the appropriate Tumour Group.

## Continuing Education

### Family Practice Oncology Network

The Family Practice Oncology Network (FPON) is pleased to announce the webinar session **Ovarian Cancer for Primary Care Providers** with Dr. Kim Stewart, on Thursday 21 November 2024, from 8 to 9 am, as part of the Complimentary Accredited Webinar Series. The session will cover:

- Current management of ovarian cancer
- Short- and long-term toxicities of treatment
- Follow-up recommendations post curative-intent ovarian cancer treatment

For more information and links to registration, visit:

<https://ubccpd.ca/learn/learning-activities/course?eventtemplate=842-fpon-webinar-ovarian-cancer-for-primary-care-providers>

## Benefit Drug List

### New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 November 2024:

Protocol Title	Protocol Code	Benefit Status
Therapy of Advanced Colorectal Cancer using <b>Trifluridine-Tipiracil</b> and <b>Bevacizumab</b>	<b>GIAVTTB</b>	Class I
Second-Line Treatment of Adults with Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma (HGBL) using <b>Axicabtagene Ciloleucl (YESCARTA)</b>	<b>LYCARTDL2</b>	Restricted
Third-Line Treatment of Adults with Follicular Lymphoma (Grade 1, 2 or 3a) using <b>Axicabtagene Ciloleucl (YESCARTA)</b>	<b>LYCARTFL3</b>	Restricted
Treatment of Unresectable or Metastatic Melanoma using <b>Nivolumab-Relatlimab</b>	<b>USMAVNIVRE</b>	Restricted

### Revised Programs

The following treatment program has been revised on the BC Cancer [Benefit Drug List](#) effective 01 November 2024:

Protocol Title	Protocol Code	Benefit Status
Third- or Later-Line Therapy of Advanced Gastroesophageal Carcinoma using <b>Trifluridine-Tipiracil</b>	<b>GIGAVTT</b> <i>(previously GIGAVTRFT)</i>	Class I

## List of New & Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter U.

### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* )

Code	Protocol Title	Protocol	PPPO	Handout
BRAJZOL2	Adjuvant Therapy for Breast Cancer in Post-Menopausal Women using 3-Monthly Zoledronic Acid	--	--	<input checked="" type="checkbox"/>
BRAJZOL5	Adjuvant Therapy for Breast Cancer in Post-Menopausal Women using Zoledronic Acid	--	--	<input checked="" type="checkbox"/>
GIAVTTB	Therapy of Advanced Colorectal Cancer using Trifluridine-Tipiracil and Bevacizumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--
USMAVNIVRE	Treatment of Unresectable or Metastatic Melanoma using Nivolumab-Relatlimab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	--

### REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>CN   Neuro-Oncology</b>				
CNAJ12TZRT	Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly-Diagnosed Malignant Gliomas with Radiation	<i>Caution, tests, precautions and references updated; renal dose modifications removed</i>	<i>Prechemo metrics and tests updated</i>	--
CNAJ TZRT	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly-Diagnosed Malignant Gliomas with Radiation	<i>Tests, dose modifications and precautions updated</i>	<i>Prechemo metrics and tests updated</i>	--
CNELTZRT	Treatment of Elderly Newly-Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy	<i>Cautions, tests, dose modifications, precautions and references updated</i>	<i>Prechemo metrics and tests updated</i>	--
CNTEM60	Therapy for Newly-Diagnosed Malignant Brain Tumours with MGMT Methylation in Elderly Patients using Temozolomide	<i>Tests, dose modifications, precautions and references updated</i>	<i>Prechemo metrics and tests updated</i>	--
CNTEMOZ	Therapy for Malignant Brain Tumours using Temozolomide	<i>Cautions, tests, dose modifications, precautions and references updated</i>	<i>Prechemo metrics and tests updated</i>	--

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>CNTEMOZMD</b>	Therapy for Malignant Brain Tumours using Metronomic Dosing of Temozolomide	<i>Cautions, tests, dose modifications, precautions and references updated</i>	<i>Prechemo metrics and tests updated</i>	--
<b>CNTMZETO</b>	Therapy for Recurrent Malignant Brain Tumours using Temozolomide and Etoposide	<i>Caution, renal dose modifications, precautions and references updated</i>	<i>Prechemo metrics and tests updated</i>	--
<b>GI   Gastrointestinal</b>				
<b>GIGAVTT</b> <i>(previously GIGAVTRFT)</i>	Third- or Later-Line Therapy of Advanced Gastroesophageal Carcinoma using Trifluridine-Tipiracil	<i>Protocol code revised; treatment clarified; tests, dose dispensing table, dose modifications and precautions updated</i>	<i>Protocol code revised; pre-chemo metrics, return appointment orders and tests updated</i>	<i>Protocol code revised</i>
<b>GU   Genitourinary</b>				
<b>GUAVIPNI</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Ipilimumab and Nivolumab	--	--	<i>Names of Centres updated</i>
<b>GUEDPM</b>	Treatment of Metastatic Adrenocortical Cancer with Etoposide, Doxorubicin, Cisplatin and Mitotane	--	<i>Pre-chemo metrics updated</i>	--
<b>GUMCSPABI</b>	Therapy for Metastatic Castration-Sensitive Prostate Cancer using Abiraterone and Prednisone	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>GUMCSPAPA</b>	Treatment of Metastatic Castration-Sensitive Prostate Cancer using Apalutamide	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>UGUMCSPDD</b>	Treatment of Metastatic Castration-Sensitive Prostate Cancer using Darolutamide and Docetaxel	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>GUMCSPENZ</b>	Treatment for Metastatic Castration-Sensitive Prostate Cancer using Enzalutamide	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>UGUNMPDAR</b>	Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Darolutamide	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>UGUNMPENZ</b>	Therapy for Non-Metastatic Castration-Resistant Prostate Cancer using Enzalutamide	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>GUOTEVER</b>	Therapy for Tuberous Sclerosis Complex-Associated High-Risk Renal Angiomyolipomas using Everolimus	<i>Tests updated</i>	<i>Dispense quantity and tests updated</i>	--
<b>UGUPABI</b>	Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using Abiraterone and Prednisone	<i>Tests updated</i>	<i>Tests updated</i>	--



## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>UGUPAJABI</b>	Therapy for Castration Sensitive Very High-Risk Non-Metastatic Prostate Cancer using Abiraterone and Prednisone	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>UGUPAPA</b>	Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Apalutamide	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>UGUPENZ</b>	Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using Enzalutamide	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>HN   Head and Neck</b>				
<b>HNAVFUP</b>	Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer using Fluorouracil and Platinum	<i>Premedications updated</i>	--	--
<b>HNAVPC</b>	Treatment for Unresectable, Locoregionally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck using Paclitaxel and Cisplatin or Carboplatin	<i>Premedications updated; hyperlinks added</i>	<i>Premedications updated</i>	--
<b>HNAVPCPMB</b>	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab	<i>Emetogenic category updated</i>	<i>Premedications updated</i>	--
<b>HNAVPD</b>	Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Platinum and Docetaxel	<i>Emetogenic category updated</i>	<i>Premedications updated</i>	--
<b>HNAVPE</b>	Treatment of Recurrent and Metastatic Squamous Cell Cancer with Platinum and Etoposide	<i>Emetogenic category updated; treatment, renal dysfunction dose modification section and precautions updated</i>	--	--
<b>HNAVFPMB</b>	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck using Platinum, Fluorouracil and Pembrolizumab	<i>Emetogenic category updated; pembrolizumab mixing info removed</i>	--	--
<b>HNLCART3</b>	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent 3-Weekly Carboplatin and Radiation	<i>Emetogenic category updated</i>	<i>Premedications updated</i>	--
<b>HNAVFUP</b>	Advanced Nasopharyngeal Cancer of the Head and Neck using Platinum and Fluorouracil	<i>Emetogenic category updated</i>	--	--
<b>HNAVPC</b>	Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma with Carboplatin and Paclitaxel	--	<i>Premedications updated</i>	--
<b>HNAVPE</b>	Treatment of Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Etoposide	<i>Emetogenic category clarified</i>	--	--

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>HNNAVPG</b>	Treatment of Locoregionally Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Gemcitabine	--	<i>Premedications updated</i>	--
<b>LK   Leukemia &amp; BMT</b>				
<b>ULKAMLAMTN</b>	Maintenance Oral Azacitidine for Acute Myeloid Leukemia	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
<b>LKAMLAS</b>	Therapy of Acute Myeloid Leukemia using Azacitidine and Sorafenib	<i>Tests and precautions updated; supportive medications section added</i>	<i>Tests updated</i>	--
<b>LKAMLCYT</b>	Therapy of Acute Myeloid Leukemia using Low-Dose Cytarabine	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
<b>LKAMLDCYT</b>	Therapy of Acute Myeloid Leukemia using Daunorubicin Liposomal-Cytarabine Liposomal	<i>Tests and precautions updated; supportive medications section added</i>	<i>Tests updated</i>	--
<b>ULKAMLGIL</b>	Therapy of Relapsed or Refractory FLT3+ Acute Myeloid Leukemia using Gilteritinib	<i>Tests and precautions updated; supportive medications added</i>	<i>Tests updated</i>	--
<b>LKANAG</b>	Anagrelide as Second-Line Treatment of Thrombocytosis Related to Myeloproliferative Disorders	<i>Tests and precautions updated</i>	--	--
<b>LKATOATRA</b>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid)	<i>Tests, supportive medications and precautions updated</i>	--	--
<b>LKATOP</b>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and Daunorubicin	<i>Tests, supportive medications and precautions updated</i>	--	--
<b>LKATOR</b>	Induction and Consolidation Therapy of Relapsed Acute Promyelocytic Leukemia using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid)	<i>Tests and precautions updated</i>	--	--
<b>ULKBLIN</b>	Treatment of Philadelphia Chromosome (Ph)-Positive or Ph-Negative Refractory or Relapsed Pre-B-Cell Acute Lymphoblastic Leukemia with Blinatumomab	<i>Tests, supportive medications and precautions updated</i>	--	--
<b>LKCMLA</b>	Treatment of Chronic Myeloid Leukemia using Asciminib	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
LKCMLB	Treatment of Chronic Myeloid Leukemia using Bosutinib	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LKCMLD	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Dasatinib	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LKCMLI	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Imatinib	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LKCMLN	Treatment of Chronic Myeloid Leukemia using Nilotinib	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
ULKCMPLP	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Ponatinib	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LKGEMOZ	Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy	<i>Tests, supportive medications and precautions updated</i>	--	--
ULKINOZ	Treatment of Relapsed or Refractory Pre-B Cell Acute Lymphoblastic Leukemia with Inotuzumab Ozogamicin	<i>Tests, supportive medications and precautions updated</i>	<i>Tests updated</i>	--
LKMDSA	Therapy of Myelodysplastic Syndrome and Acute Myeloid Leukemia using Azacitidine	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
ULKMDSDC	Therapy of Myelodysplastic Syndrome using Decitabine-Cedazuridine	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
LKMDSL	Therapy of Myelodysplastic Syndrome using Lenalidomide	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
ULKMFFED	Treatment of Symptomatic Myelofibrosis with Fedratinib	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
LKMFRUX	Treatment of Symptomatic Myelofibrosis with Ruxolitinib	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
ULKMRDBLIN	Treatment of Pre-B-Cell Acute Lymphoblastic Leukemia with Minimal Residual Disease using Blinatumomab	<i>Tests, supportive medications and precautions updated</i>	--	--
LKPCVRUX	Treatment of Polycythemia Vera with Ruxolitinib	<i>Tests and precautions updated</i>	<i>Tests updated</i>	--
<b>LU   Lung</b>				
LUMMIPNI	Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab	--	--	<i>Names of Centres updated</i>
LUMMIPNI3	Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab	--	--	<i>Names of Centres updated</i>

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Code	Protocol Title	Protocol	PPPO	Handout
<b>SC   Supportive Care</b>				
<b>SCCRS</b>	Cytokine Release Syndrome Management	<i>Preamble, tests and treatment updated</i>	<i>Grade 2, Grade 3 to 4 treatment and tests updated</i>	--
<b>SCICANS</b>	Immune Effector Cell-Associated Neurotoxicity Syndrome Management	--	<i>Anakinra bag size updated</i>	--
<b>SCPAINSU</b>	Incident Pain Therapy using Sufentanil via Sublingual Route	<i>Naloxone order and monitoring added; precautions removed</i>	<i>Sedation scale updated; naloxone orders added</i>	--
<b>SM   Skin &amp; Melanoma</b>				
<b>SMAJNIV</b>	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using Nivolumab	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>SMAJNIV4</b>	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using 4-Weekly Nivolumab	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>SMAJPEM</b>	Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma using Pembrolizumab	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>SMAJPEM6</b>	Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma using 6-Weekly Pembrolizumab	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>SMAVALIPNI</b>	Treatment of Unresectable or Metastatic Melanoma using Alternative Dosing Regimen of Ipilimumab and Nivolumab	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	<i>Duplicate alert card deleted</i>
<b>SMAVCEM</b>	Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cemiplimab	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>SMAVFIPI</b>	First-Line Treatment of Unresectable or Metastatic Melanoma using Ipilimumab	<i>Tests updated</i>	<i>Tests updated</i>	--
<b>SMAVIPI</b>	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	--
<b>SMAVIPNI</b>	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab and Nivolumab	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	<i>Duplicate alert card deleted</i>
<b>SMAVNIV</b>	Treatment of Unresectable or Metastatic Melanoma using Nivolumab	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	--
<b>SMAVNIV4</b>	Treatment of Unresectable or Metastatic Melanoma using 4-Weekly Nivolumab	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	--
<b>SMAVPEM</b>	Treatment of Unresectable or Metastatic Melanoma using Pembrolizumab	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	--
<b>SMAVPEM6</b>	Treatment of Unresectable or Metastatic Melanoma using 6-Weekly Pembrolizumab	<i>Eligibility and tests updated</i>	<i>Tests updated</i>	--
<b>SMMCCAWE</b>	Second-Line Treatment of Recurrent or Metastatic Merkel Cell Carcinoma using Avelumab	<i>Tests updated</i>	<i>Tests updated</i>	--

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCCancerPPNAdmin@phsa.ca">BCCancerPPNAdmin@phsa.ca</a>
Provincial Systemic Therapy Network	604-877-6000 x 672247	<a href="mailto:ProvincialSystemicOffice@bccancer.bc.ca">ProvincialSystemicOffice@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)  
 Jelena Mucovic, BScPharm (Assistant Editor)  
 Jeevan Dosanjh, RN, BScN

Alina Gerrie, MD, MPH, FRCPC  
 Alison Pow, BScPharm  
 Yuna Jang, RN